PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 40,290 Shares

PTC Therapeutics, Inc. (NASDAQ:PTCT) insider Eric Pauwels sold 40,290 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $75.43, for a total value of $3,039,074.70. Following the sale, the insider directly owned 70,373 shares in the company, valued at approximately $5,308,235.39. This trade represents a 36.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Eric Pauwels also recently made the following trade(s):

• On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.06, for a total value of $240,342.12.

PTC Therapeutics Stock Up 5.3%

PTC Therapeutics stock traded up $3.98 during mid-day trading on Friday, hitting $78.57. 2,735,148 shares of the company’s stock traded hands, compared to its average volume of 1,223,774. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50. The firm has a 50 day moving average price of $73.32 and a 200 day moving average price of $59.78. The company has a market cap of $6.31 billion, a PE ratio of 9.18, a price-to-earnings-growth ratio of 0.27 and a beta of 0.47.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a negative return on equity of 194.11% and a net margin of 42.25%.The company had revenue of $211.01 million during the quarter, compared to analysts’ expectations of $177.42 million. During the same quarter in the prior year, the business posted ($1.39) earnings per share. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. On average, analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors have recently bought and sold shares of PTCT. Ameritas Investment Partners Inc. lifted its stake in PTC Therapeutics by 3.0% during the second quarter. Ameritas Investment Partners Inc. now owns 7,936 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 231 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 236 shares during the period. Optiver Holding B.V. raised its holdings in shares of PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 249 shares during the period. PNC Financial Services Group Inc. lifted its position in shares of PTC Therapeutics by 42.1% in the 2nd quarter. PNC Financial Services Group Inc. now owns 995 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 295 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in PTC Therapeutics by 68.1% in the 3rd quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 310 shares during the period.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wells Fargo & Company upped their price target on shares of PTC Therapeutics from $73.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Cowen reaffirmed a “hold” rating on shares of PTC Therapeutics in a research note on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of PTC Therapeutics in a research note on Monday. Wall Street Zen lowered PTC Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Royal Bank Of Canada lowered PTC Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their target price for the stock from $82.00 to $91.00 in a report on Monday, December 1st. Nine analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, PTC Therapeutics presently has an average rating of “Hold” and an average target price of $76.00.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.